Table 2. Worst toxicity grade on allocated treatment – nonhaematological toxicities.
| wTCFa/X N=39 (%) |
wTCF/X+panitumumab N=37(%) |
|||
|---|---|---|---|---|
| Toxicity | Any grade | Grade ⩾3 | Any grade | Grade ⩾3 |
| Infections with normal neutrophils | 13 (33.3) | 7 (17.9) | 23 (62.1) | 9 (24.3) |
| Infections with abnormal (low) neutrophils | 2 (5.2) | 1 (2.6) | 2 (5.4) | 0 (0) |
| Febrile neutropenia | 4 (10.3) | 4 (10.3) | 2 (5.4) | 2 (5.4) |
| Anorexia | 25 (64.1) | 4 (10.3) | 28 (59.4) | 9 (24.3) |
| Nausea | 30 (76.8) | 7 (17.9) | 33 (70.2) | 11 (29.7) |
| Vomiting | 22 (56.4) | 6 (15.4) | 45 (62.1) | 6 (16.2) |
| Diarrhoea | 26 (66.7) | 6 (15.4) | 31 (83.7) | 9 (24.3) |
| Dysphagia | 6 (28.2) | 2 (5.1) | 17 (45.9) | 4 (10.8) |
| Stomatitis | 18 (46.2) | 1 (2.6) | 22 (59.4) | 2 (5.4) |
| Hair loss/alopecia | 28 (71.8) | 0 (0.0) | 23 (62.1) | 0 (0.0) |
| Rash: acne/acneiform | 11 (28.2) | 0 (0.0) | 35 (94.5) | 3 (8.1) |
| Rash: hand-foot skin reaction | 24 (61.5) | 4 (10.3) | 24 (64.8) | 2 (5.4) |
| Nail changes | 17 (43.6) | 0 (0.0) | 10 (27.0) | 0 (0.0) |
| Neuropathy – motor | 1 (2.6) | 0 (0.0) | 1 (2.7) | 1 (2.7) |
| Neuropathy – sensory | 20 (41.0) | 0 (0.0) | 14 (37.4) | 0 (0.0) |
| Allergic reaction/ hypersensitivity | 7 (18.0) | 1 (2.6) | 7 (18.9) | 1 (2.7) |
| Fatigue | 36 (92.3) | 7 (17.9) | 34 (91.8) | 11 (29.7) |
| Watery eyes | 11 (28.2) | 1 (2.6) | 8 (21.7) | 1 (2.7) |
| Hearing impairment | 1 (2.6) | 0 (0.0) | 3 (8.1) | 1 (2.7) |
| Pain: headache | 5 (12.9) | 0 (0.0) | 5 (13.5) | 1 (2.7) |
| Other toxicity | 38 (97.4) | 23 (58.9) | 36 (97.2) | 36 (59.4) |
a
Weekly docetaxel, cisplatin and a fluoropyrimidine (5-fluorouracil or capecitabine).